Foundayo delivers positive data: LLY resistance levels in focus

Traders Union
All News
Stocks
Eli Lilly jumps 3.85% to $1,202 today

Highlights

Eli Lilly secured expanded FDA approval for Jaypirca for first-line use in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletion, broadening its eligible patient pool.
ETF inflows totaled $426.6 million on October 2, as the company advances cardiovascular, metabolic, and pipeline assets despite winding down a Foghorn Therapeutics collaboration.
Shares of Eli Lilly are trading with clear short- and long-term bullish momentum, with the price up 3.85% and expected to hold in the $1,186 to $1,218 range over the next 2 to 3 days.

FDA approval and institutional buying expand growth prospects

Eli Lilly has secured expanded FDA approval for Jaypirca, allowing its first-line use in adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion, according to Kalkinemedia. This key regulatory milestone is expected to increase demand and broaden revenue potential by giving the company access to a larger patient base. Additional momentum comes from positive cardiovascular and metabolic results for Foundayo, as well as notable institutional inflows with ETFs acquiring $426.6 million in shares on October 2, as reported by Kalkinemedia and Gurufocus. While the winding down of the Foghorn Therapeutics collaboration narrows parts of the late-stage pipeline, ongoing developments such as the Phase 1 completion for Eltrekibart, asset stake in TRex Bio’s IPO filing, and support for Forbion’s biotechnology fund reinforce the company’s strategic positioning and future growth levers.

Buyer dominance persists as technicals signal mixed momentum

Looking at chart levels, LLY/USD remains above the MA-20 ($1,150) and MA-50 ($1,163) on the hourly timeframe, with the daily MA-200 at $1,074 providing a longer-term floor. Immediate support is defined by the Ichimoku Kijun at $1,156, while resistance is seen near today’s session highs. Among momentum indicators, RSI is neutral-bullish at 52.2 (Buy), CCI signals Buy, MACD and ADX remain Neutral, and Stochastic RSI is also Neutral. Bull/Bear Power points to strong buyer dominance and is classified as Overbought, with Awesome Oscillator confirming upward movement. However, mixed readings from several oscillators highlight divergent momentum signals and warrant caution.

Range-bound price action likely unless new catalyst emerges

In the near term, LLY is expected to trade between $1,186 and $1,218 over the next two to three trading days, reflecting a typical volatility range relative to current levels. The baseline scenario suggests price action will consolidate within this corridor unless a catalyst emerges. A breakout above $1,218 would confirm a continuation of bullish momentum, targeting further gains, while a move below $1,186 could signal the start of a corrective pullback.

Anton Kharitonov, expert at Traders Union, sees Eli Lilly’s strong uptrend supported by material news and institutional flows, but remains cautious given mixed technical readings. He notes that expanded Jaypirca approval is a clear catalyst, while recent ETF inflows and drug data highlight ongoing interest. However, risks from a narrowing pipeline and divergent indicators temper bullish conviction. "Until LLY can firmly break above $1,218, my base case is rangebound action with a risk of corrective pullback if $1,186 is breached."

Earlier, analysts noted that Eli Lilly shares were consolidating in a narrow range, reflecting mixed momentum signals and caution around key technical levels. The current price action, underpinned by expanded regulatory approvals and fresh institutional inflows, reinforces the importance of monitoring the $1,218 resistance as a potential trigger for renewed directional movement in the days ahead.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.